<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7092853/results/search/test_trace/results.xml">
  <result pre="Inc. pmcid: 7092853S0006-291X(19)32332-0 doi: 10.1016/j.bbrc.2019.12.012 : Article Cephalotaxine inhibits Zika" exact="infection" post="by impeding viral replication and stability LaiZheng-ZongabcHoYi-Jungde∗∗LuJeng-Weijengweilu@gmail.comf∗[a], [b], [c],"/>
  <result pre="that CET could be an effective lead compound in the" exact="treatment" post="of ZIKV and also suggest that further investigation and"/>
  <result pre="a new class of anti-Flavivirus medications. Highlights •CET against ZIKV" exact="infection" post="via inhibiting replication and stability. •CET was identified as"/>
  <result pre="NS4A, NS4 B, and NS5 [3]. In recent years, ZIKV" exact="infection" post="has become a serious and escalating threat to global"/>
  <result pre="0.5 and 1.5 million people [[4], [5], [6], [7]]. ZIKV" exact="infection" post="has been associated with several neurological complications, such as"/>
  <result pre="affected Brazil and other Central and South American countries, ZIKV" exact="infection" post="was only considered to lead only to a mild"/>
  <result pre="vomiting and jaundice [11]. Other clinical symptoms typical of ZIKV" exact="infection" post="include fever, headaches, joint pain, conjunctivitis, and macular atrophy"/>
  <result pre="Emergency of International Concern (PHEIC) [13]. Strategies of fighting ZIKV" exact="infection" post="include the development of vaccines and the screening of"/>
  <result pre="fighting ZIKV infection include the development of vaccines and the" exact="screening" post="of antiviral agents that inhibit different stages of the"/>
  <result pre="drugs are also believed to have great potential in the" exact="treatment" post="of other diseases, including some cancers [18]. HT inhibits"/>
  <result pre="that both HT and HHT are promising candidates for the" exact="treatment" post="of diseases related to the varicella-zoster virus (VZV) [16,[19],"/>
  <result pre="a serial dilution of virus medium. Following a 2 h" exact="infection" post="period, the cells were overlaid with DMEM containing 1.5%"/>
  <result pre="of cells was extracted 24 or 48 h after CET" exact="treatment" post="using Trizol reagent (Ambion). Gene expression was then quantified"/>
  <result pre="at various time points as follows. (1) For the full-duration" exact="treatment" post="group, CET was added throughout the infection period. (2)"/>
  <result pre="For the full-duration treatment group, CET was added throughout the" exact="infection" post="period. (2) For the co-treatment group, CET was added"/>
  <result pre="before ZIKV infection. Following ZIKV infection, Vero cells in all" exact="treatment" post="groups were incubated at 37 °C for 24 h,"/>
  <result pre="significant [[22], [23], [24]]. 3 Results 3.1 CET inhibited ZIKV" exact="infection" post="Earlier research found that CET was able to inhibit"/>
  <result pre="Earlier research found that CET was able to inhibit HBV" exact="infection" post="[16]; however, the anti-viral effects of CET against other"/>
  <result pre="that CET from 20 to 100 μM significantly inhibited ZIKV" exact="infection" post="in a dose-dependent manner (Fig. 1 A, B, and"/>
  <result pre="were employed. Results of qRT-PCR showed that CET inhibited ZIKV" exact="infection" post="in a dose-dependent manner (Fig. 2B). In particular, a"/>
  <result pre="revealed that ZIKV protein expression was significantly reduced under CET" exact="treatment" post="(Fig. 2C). Results of FFU assays revealed that CET"/>
  <result pre="Our data indicated that CET is able to inhibit ZIKV" exact="infection" post="by decreasing viral RNA, protein, and progeny yield. Therefore,"/>
  <result pre="added to Vero cells in pre-treatment, co-treatment, post-treatment, and full-duration" exact="treatment" post="groups. (Cells in all groups were infected with 8000"/>
  <result pre="per well for 1 h) Following the end of the" exact="infection" post="period, cells were washed two times and the medium"/>
  <result pre="revealed that CET likely affects the late stage of ZIKV" exact="infection" post="(Fig. 3 A and B), which means that the"/>
  <result pre="further analysis. Results showed that administering CET after the initial" exact="infection" post="(i.e., the post-treatment group) suppressed viral RNA replication. In"/>
  <result pre="virus progeny production. The effects of administering CET after ZIKV" exact="infection" post="(i.e., the post-treatment group) as revealed by (C) qRT-PCR"/>
  <result pre="Results of a virucidal assay which assessed the effects of" exact="treatment" post="with 40 μM CET. The data shown here represent"/>
  <result pre="CET also has the potential to be used in the" exact="treatment" post="of dengue virus infection. Fig. 4 Inhibition of CET"/>
  <result pre="in different serotypes of dengue virus. (A–D) Effects of CET" exact="treatment" post="on DENV1-4. The anti-dengue ability of CET was determined"/>
  <result pre="date, despite significant efforts to develop effective vaccines, no effective" exact="treatment" post="for this emerging pathogen has been found. Therefore, identifying"/>
  <result pre="antiviral drugs and effective clinical compounds is critical for the" exact="treatment" post="of ZIKV patients and for the control of ZIKV"/>
  <result pre="inhibits ZIKV infection. Specifically, results of IFA revealed that CET" exact="treatment" post="reduced viral infection in both Vero and A549 cells"/>
  <result pre="Specifically, results of IFA revealed that CET treatment reduced viral" exact="infection" post="in both Vero and A549 cells (Fig. 1). Researchers"/>
  <result pre="assay showed that CET affected the late stage of ZIKV" exact="infection" post="(Fig. 3A and B). We further sought to determine"/>
  <result pre="addition assay showed that the viral yield of the full-duration" exact="treatment" post="group was lower than that of the post-treatment group"/>
  <result pre="our data indicate that CET is able to inhibit ZIKV" exact="infection" post="by affecting both viral replication and viral stability. Finally,"/>
  <result pre="(Fig. 4). Therefore, CET may also be useful in the" exact="treatment" post="of dengue virus infections. To conclude, our results indicate"/>
  <result pre="Res.1672019132430959074 9ChenJ.LiangY.YiP.XuL.HawkinsH.K.RossiS.L.SoongL.CaiJ.MenonR.SunJ.Outcomes of congenital Zika disease depend on timing of" exact="infection" post="and maternal-fetal interferon actionCell Rep.2120171588159929117563 10ChibuezeE.C.TiradoV.LopesK.D.BalogunO.O.TakemotoY.SwaT.DagvadorjA.NagataC.MorisakiN.MenendezC.OtaE.MoriR.OladapoO.T.Zika virus infection in"/>
  <result pre="timing of infection and maternal-fetal interferon actionCell Rep.2120171588159929117563 10ChibuezeE.C.TiradoV.LopesK.D.BalogunO.O.TakemotoY.SwaT.DagvadorjA.NagataC.MorisakiN.MenendezC.OtaE.MoriR.OladapoO.T.Zika virus" exact="infection" post="in pregnancy: a systematic review of disease course and"/>
  <result pre="chikungunya virus through multiple mechanismsAntivir. Res.159201813414230300716 23HoY.J.LuJ.W.HuangY.L.LaiZ.Z.Palmatine inhibits Zika virus" exact="infection" post="by disrupting virus binding, entry, and stabilityBiochem. Biophys. Res."/>
  <result pre="entry, and stabilityBiochem. Biophys. Res. Commun.518201973273831472967 24LuJ.W.HsiehP.S.LinC.C.HuM.K.HuangS.M.WangY.M.LiangC.Y.GongZ.HoY.J.Synergistic effects of combination" exact="treatment" post="using EGCG and suramin against the chikungunya virusBiochem. Biophys."/>
  <result pre="J. Biochem.721977323330319998 28JiaK.YuanY.LiuW.LiuL.QinQ.YiM.Identification of inhibitory compounds against Singapore grouper iridovirus" exact="infection" post="by cell viability-based screening assay and droplet digital PCRMar."/>
  <result pre="inhibitory compounds against Singapore grouper iridovirus infection by cell viability-based" exact="screening" post="assay and droplet digital PCRMar. Biotechnol.202018354429209860 29HuangM.T.Harringtonine, an inhibitor"/>
 </snippets>
</snippetsTree>
